CI Price Prediction Next Week
Based on the provided data and technical analysis, here is the price prediction for CI (Cigna) for the next trading week:
Technical Analysis
The stock is currently trading at $293.64, showing mixed signals:
- Fibonacci levels indicate key resistance at $295.20 (R1) and $300.62 (R2)
- Support levels are at $277.62 (S1) and $272.20 (S2)
- RSI at 55.92 suggests neutral momentum
- Stock is trading below its 200-day SMA of $329.11, indicating a bearish long-term trend
- Currently trading above 20-day SMA of $282.40, showing short-term strength
News Sentiment Analysis Recent news shows mixed sentiment:
- Positive: Elevance Health's better-than-expected earnings boosted health insurance stocks
- Negative: Potential regulatory pressures and Medicaid funding cuts under a possible Republican administration
Price Target for Next Week Based on technical indicators and news sentiment:
- Resistance: $295-300 range
- Support: $277-282 range
- Most likely scenario: Stock will test R1 at $295.20 but face resistance
- Price target: $297 (+1.1% from current price)
Trading Recommendation BUY with entry at current levels ($293.64) with tight stop loss at $290. The positive sector sentiment from Elevance Health's earnings combined with oversold conditions in healthcare stocks suggests upside potential, though gains may be limited by broader regulatory concerns.
CI Similar Chart Price Prediction
The price of CI is predicted to go up 3.37%, based on the high correlation periods with MD. The similarity of these two price pattern on the periods is 92.68%.
CI
MD
Up: 3.37%Similarity: 92.68%
CI Revenue Forecast
CI EPS Forecast
CI FAQs
What is revenue forecast for next quarter？
What is eps forecast for next quarter？
CI VS S&P500
Combining with Express Scripts gave Cigna more tools to help clients control their healthcare costs, and we see significant cross-selling opportunities across their respective books of business.
With its strong medical cost trend history and goal to reduce that trend to the low-single-digits, Cigna should be able to benefit from continued enrollment gains in the more profitable commercial segment.
Cigna's organic earnings growth prospects look solid both with and without capital-allocation activities, such as share repurchases.
CI Analyst's Forecast
Jessica Tassan
Piper Sandler
Buy
Price Target
$392 → $394
Upside
+23.76%
Piper Sandler raised the firm's price target on Cigna to $394 from $392 and keeps an Overweight rating on the shares. The firm notes Cigna reported a pharmacy-led Q3 adjusted EPS beat and reiterated adjusted 2024 guidance. Notwithstanding the asset sale at Cigna Healthcare and VillageMD headwind at Evernorth, CI expects 10.0%-plus consolidated adjusted EPS growth in 2025 vs. long-term target range of 10.0% to 14.0%, Piper adds.
David Windley
Jefferies
Strong Buy
Price Target
$402 → $422
Upside
+18.7%